SkinHealth Systems Inc. (SKIN)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NASDAQ
Market Cap: $106.26M
Last updated: Nov 17, 2026 at 11:01 AM ET
SkinHealth Systems Inc. (SKIN) Stock Forecast
Analysts expect SkinHealth Systems (SKIN) to earn $1.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $285.17M. Of 9 analysts, 1 rates the stock Buy or Strong Buy, 6 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 3.33, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 22% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 11.1% |
| Hold | 6 | 66.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 2 | 22.2% |
- Consensus
- Hold
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 76.8% and revenue estimates rise 1.3%.
- Fiscal year ending Dec 31, 2026
- $1.90
- EPS consensus, revenue $285.17M
- Fiscal year ending Dec 31, 2027
- $3.36
- EPS consensus, revenue $288.89M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.90 | $1.90 to $1.90 | 1 | $285.17M | $283.37M to $286.90M | 9 |
| Dec 31, 2027 | $3.36 | $3.36 to $3.36 | 1 | $288.89M | $282.90M to $295.49M | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.47 for the quarter ending Dec 31, 2026 to -$0.75 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.47 | -$0.96 to -$0.14 | 11 | $81.25M | $76.34M to $87.36M | 11 |
| Mar 31, 2027 | -$0.75 | -$0.99 to -$0.52 | 4 | $65.10M | $62.90M to $68.10M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 2 |
EPS Trend
Over the last 60 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 26.9% from $2.60.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.90 | $2.56 | $2.60 | $2.60 | N/A | N/A |
| Fiscal year ending Dec 31, 2027 | $3.36 | $3.82 | $3.80 | $3.80 | $3.00 | +12.0% |
| Quarter ending Mar 31, 2027 | -$0.75 | -$0.44 | -$0.44 | -$0.44 | -$0.44 | N/A |
Frequently Asked Questions About SKIN
What is the SKIN stock forecast?
Consensus analyst estimates put SkinHealth Systems's EPS at $1.90 for the fiscal year ending Dec 31, 2026, on revenue of $285.17M. The consensus rating from 9 analysts is Hold.
How do analysts rate SKIN stock?
Of 9 analysts covering SkinHealth Systems, 0 rate it Strong Buy, 1 Buy, 6 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from SKIN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.90, with estimates from $1.90 to $1.90 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.36, with estimates from $3.36 to $3.36 from 1 analyst.
What revenue do analysts expect from SkinHealth Systems next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $285.17M, with estimates from $283.37M to $286.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $288.89M, with estimates from $282.90M to $295.49M.
How many analysts cover SKIN?
9 analysts rate SkinHealth Systems stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
SKIN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors